Kidney Cancer

>

Latest News

Data from the phase 3 ZIRCON study support the biologics license application for TLX250-CDx in clear cell renal cell carcinoma imaging.
FDA Grants Priority Review to TLX250-CDx in Clear Cell RCC Imaging

February 26th 2025

Data from the phase 3 ZIRCON study support the biologics license application for TLX250-CDx in clear cell renal cell carcinoma imaging.

Longer progression-free survival and more enduring responses occurred with avelumab/axitinib vs sunitinib in the phase 3 JAVELIN Renal 101 trial.
Avelumab Combo Improves Long-Term Efficacy Vs Sunitinib in Advanced RCC

February 26th 2025

LITESPARK-004 and LITESPARK-005 trial results support the approval of belzutifan in patients with associated localized or advanced clear cell RCC.
Belzutifan Receives European Approval in Localized/Advanced RCC Indications

February 18th 2025

PROs Comparable with Tivozanib Alone or With Nivolumab in Advanced Clear Cell RCC
PROs Comparable with Tivozanib Alone or With Nivolumab in Advanced Clear Cell RCC

February 16th 2025

Cabozantinib Combo Yields Sustained PFS at Follow-Up in Advanced RCC
Cabozantinib Combo Yields Sustained PFS at Follow-Up in Advanced RCC

February 15th 2025

Video Series
Video Interviews
Podcasts
Two oncologists discuss the impact of advocacy in kidney cancer research, highlighting collaboration between researchers, advocates, and physicians.
Experts discuss findings related to liquid biopsy profiling, later-line immunotherapy, and CDK4/6 inhibitor efficacy presented at the 2024 KCRS meeting.
Santosh Rao, MD, discusses the formation of new guidelines informing the use of integrative oncology for patients with kidney cancer from the Society for Integrative Oncology.

More News